Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Koopman

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|January 1, 2026
Temporal modulation of gene expression in a controlled <i>Schistosoma mansoni</i> human infection modelDawei Li, Chuan Jiang, Wenyu Zhu, et al.
Nature Communications|July 24, 2025
T cell responses in repeated controlled human schistosome infection compared to natural exposureEmmanuella Driciru, Jan Pieter R Koopman, Sanne Steenbergen, et al.
Nature Communications|June 12, 2026
Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trialA D O Hensen, C Harmanus, P H Verbeek-Menken, et al.
The Lancet. Infectious Diseases|July 6, 2023
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the NetherlandsJohan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, et al.
Nature Communications|May 18, 2021
Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic diseaseK I Watt, D C Henstridge, M Ziemann, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
NPJ Vaccines|January 3, 2024
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trialManon L M Prins, Geert V T Roozen, Cilia R Pothast, et al.
Ebiomedicine|October 14, 2023
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection studyJan Pieter R Koopman, Emma L Houlder, Jacqueline J Janse, et al.
Nature Medicine|February 19, 2020
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnosticsMarijke C C Langenberg, Marie-Astrid Hoogerwerf, Jan Pieter R Koopman, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|January 1, 2026
Temporal modulation of gene expression in a controlled <i>Schistosoma mansoni</i> human infection modelDawei Li, Chuan Jiang, Wenyu Zhu, et al.
Nature Communications|July 24, 2025
T cell responses in repeated controlled human schistosome infection compared to natural exposureEmmanuella Driciru, Jan Pieter R Koopman, Sanne Steenbergen, et al.
Nature Communications|June 12, 2026
Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trialA D O Hensen, C Harmanus, P H Verbeek-Menken, et al.
The Lancet. Infectious Diseases|July 6, 2023
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the NetherlandsJohan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, et al.
Nature Communications|May 18, 2021
Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic diseaseK I Watt, D C Henstridge, M Ziemann, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
NPJ Vaccines|January 3, 2024
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trialManon L M Prins, Geert V T Roozen, Cilia R Pothast, et al.
Ebiomedicine|October 14, 2023
Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection studyJan Pieter R Koopman, Emma L Houlder, Jacqueline J Janse, et al.
Nature Medicine|February 19, 2020
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnosticsMarijke C C Langenberg, Marie-Astrid Hoogerwerf, Jan Pieter R Koopman, et al.
Pageof 7